Galena Biopharma (SLS)
(Delayed Data from NSDQ)
$1.14 USD
+0.02 (1.79%)
Updated Jul 3, 2024 01:00 PM ET
After-Market: $1.14 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
F Value F Growth C Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
SLS 1.14 +0.02(1.79%)
Will SLS be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for SLS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for SLS
Galena Biopharma (SLS) Upgraded to Buy: Here's What You Should Know
SELLAS (SLS) Rises on FDA Fast Track Tag to Leukemia Candidate
SLS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Galena Biopharma, Inc. (SLS) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
Other News for SLS
Solstice Minerals Director Increases Shareholding
Solaris Reports 11,570 g/t Silver and 12.3 g/t Gold in First Assays From Sampling Epithermal Mineralization Discovered As Part of Warintza Regional Exploration Program
Solaris Unveils High-Grade Silver and Gold Assays
Solaris Announces Results of Annual General Meeting of Shareholders
SELLAS Announces U.S. FDA Rare Pediatric Disease Designation Granted to SLS009 for the Treatment of Pediatric Acute Lymphoblastic Leukemia